Clinical trial · Interventional
Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Analysis of somatic mutations in tumors is currently indicated for daily practice in all metastatic melanoma. Actually, this research is limited to the mutation of three biomarkers validated by the l'Institut National du CAncer (INCA): BRAF, NRAS and CKIT. Moreover, in some cases it requires invasive biopsies. In this context, molecular characterization of a tumor material flowing (circulating tumor DNA and / or circulating tumor cells) could afford to benefit patients in the best conditions of current targeted therapies and future.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| patients with metastatic melanoma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients with metastatic melanoma
- description
- patients with metastatic melanoma (stage III unresectable or stage IV)
- interventionNames
- Other: patients with metastatic melanoma
Primary outcomes (1)
- measure
- Diagnostic sensitivity of a panel of biomarker on the circulating tumor DNA from peripheral blood
- timeFrame
- Day 0
- description
- Number of patients for which a circulating tumor DNA is detected (positivity of at least one marker of the panel)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient with melanoma confirmed histologically * patient with metastatic melanoma (stage III unresectable or stage IV) * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years Exclusion Criteria: \- Metastatic tumor whose origin is doubtful (uncertain melanoma)
References
Publications (1)
- RESULTBeaudoux O, Riffaud L, Barbe C, Grange F. Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France. Eur J Dermatol. 2018 Oct 1;28(5):654-660. doi: 10.1684/ejd.2018.3398. PMID 30378540